Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
112M
-
Number of holders
-
344
-
Total 13F shares, excl. options
-
74.2M
-
Shares change
-
+716K
-
Total reported value, excl. options
-
$12.8B
-
Value change
-
+$247M
-
Put/Call ratio
-
0.73
-
Number of buys
-
204
-
Number of sells
-
-117
-
Price
-
$173.04
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q4 2020
415 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q4 2020.
NovoCure Ltd - Common Stock (NVCR) has 344 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 74.2M shares
of 112M outstanding shares and own 66.22% of the company stock.
Largest 10 shareholders include FMR LLC (9.63M shares), BAILLIE GIFFORD & CO (8.26M shares), Capital International Investors (8.26M shares), VANGUARD GROUP INC (8.24M shares), Capital World Investors (7.75M shares), BlackRock Inc. (5.8M shares), STATE STREET CORP (1.93M shares), CREDIT SUISSE AG/ (1.45M shares), MORGAN STANLEY (1.35M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.24M shares).
This table shows the top 344 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.